Actively Recruiting
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Led by Peking University People's Hospital · Updated on 2026-02-24
163
Participants Needed
4
Research Sites
157 weeks
Total Duration
On this page
Sponsors
P
Peking University People's Hospital
Lead Sponsor
P
Peking University First Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Presently, multiparameter flow cytometry (MFC) and polymerase chain reaction (PCR) have been used for disease load, including measurable residual disease (MRD), monitoring in patients with myelodysplastic syndrome (MDS). MFC is the most commonly method for disease load evaluation. In patients with acute myeloid leukemia, leukemia stem cells (LSCs) determined using MFC for leukemia load and MRD detection is superior to traditional MFC method. In the investigators previous single center study, the investigators demonstrated that detection of disease load, including MRD, by MFC in patients with MDS-EB is superior to predict outcomes after allogeneic stem cell transplantation. Here, the investigators will perform a multi-center, prospective clinical trial to investigate the predictive values of MDS-SC in patients with MDS-EB who received allografting.
CONDITIONS
Official Title
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Myelodysplastic syndromes
- Between 15 and 70 years old
- Subjects are able to provide written informed consent.
You will not qualify if you...
- Subjects who cannot comply with the study
- Patient has severe cardiac (ejection fraction <50%), hepatic (total bilirubin >34bcmol/L, ALT, AST >2x upper limit of normal) or renal (blood creatinine >130bcmol/L) disease
- Uncontrolled serious infection
- Other conditions that do not tolerate transplantation or other therapies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Chinese PLA General Hospital
Beijing, China
Actively Recruiting
2
Peking University People's Hospital
Beijing, China
Actively Recruiting
3
Wuhan TongJi Hospital
Wuhan, China
Actively Recruiting
4
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Actively Recruiting
Research Team
C
chief physician
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here